Trends in Life Science Finance
Come hear an an overview of the private market capital flows (it’s no longer just about VCs!), public market capital flows (reversion to the mean), as well as the role debt capital is playing in the market (too much of a good thing?!?). I will also highlight examples of where there are disconnect in the market with identified risks and returns.
David M. Sabow is the Head of Silicon Valley Bank’s life science and healthcare practice, client funds and products. He manages deal teams across the country, drives the sales and marketing strategy, assists with the structuring of complex credits and presents regularly at global industry conferences. With more than 15 years of life science and healthcare finance experience, David’s background includes structuring senior and subordinated debt, IPOs, follow-on offerings, mergers & acquisitions and strategic advisory roles across the sector. Prior to joining Silicon Valley Bank, David spent nine years in the life science investment banking practice at Canaccord Genuity, with responsibility for both domestic and international deals across the life science and healthcare spectrum, specializing in public financings and M&A transactions with an aggregate deal value in excess of $1 billion. Before Canaccord, David worked as a relationship manager with U.S. Bank.